AbbVie Receives European Commission Approval of ELAHERE® …
12 hours ago · "The approval of ELAHERE by the European Commission provides a much needed clinically meaningful option for patients who receive the heartbreaking news their ovarian cancer has returned, fearing ...
AbbVie Receives European Commission Approval of ELAHERE
9 hours ago · “The approval of ELAHERE by the European Commission provides a much needed clinically meaningful option for patients who receive the heartbreaking news their ovarian cancer has returned, fearing what’s next in their treatment journey after they’ve developed platinum-resistance,” said Roopal Thakkar, M.D., executive vice president ...
AbbVie Receives European Commission Approval of ELAHERE® …
12 hours ago · AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor ...
AbbVie Gets European OK of Elahere in Platinum-Resistant
7 hours ago · AbbVie has won European Commission approval of Elahere to treat adult patients with a type of ovarian cancer. ... Dow Jones Newswires is a market-moving financial and business news source, used by ...
U.S. Food and Drug Administration (FDA) Grants Full Approval for ... - News
NORTH CHICAGO, Ill., March 22, 2024 / PRNewswire / -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval for ELAHERE® (mirvetuximab soravtansine-gynx) for the treatment of folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary ...
Mirvetuximab Soravtansine-Gynx Approved for Ovarian Cancer
Apr 24, 2024 · Platinum-resistant ovarian cancer has proven difficult to treat, but with the Food and Drug Administration’s recent full approval of mirvetuximab soravtansine-gynx (Elahere), some people in this situation now have a new treatment option.
FDA approves mirvetuximab soravtansine-gynx (Elahere, …
On March 22, 2024, the Food and Drug Administration approved mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) for adult patients with FRα positive,...
AbbVie Completes Acquisition of ImmunoGen - Feb 12, 2024
Feb 12, 2024 · AbbVie Completes Acquisition of ImmunoGen. Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio. ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative ...
AbbVie to Acquire ImmunoGen, including its Flagship Cancer ... - News
Nov 30, 2023 · ELAHERE ® is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer; ImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand into earlier lines of therapy and additional patient populations
FDA grants accelerated approval to mirvetuximab soravtansine …
On November 14, 2022, the Food and Drug Administration granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc.) for adult patients with folate receptor alpha...
- Some results have been removed